Bausch Health Companies Inc. (TSE:BHC - Get Free Report) insider Mirza Dautbegovic sold 20,000 shares of Bausch Health Companies stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of C$11.18, for a total transaction of C$223,600.00. Following the transaction, the insider directly owned 224,745 shares in the company, valued at approximately C$2,512,649.10. The trade was a 8.17% decrease in their ownership of the stock.
Bausch Health Companies Stock Performance
Shares of TSE:BHC opened at C$11.56 on Friday. The company has a market capitalization of C$4.33 billion, a price-to-earnings ratio of -5.12, a price-to-earnings-growth ratio of 0.21 and a beta of 0.73. Bausch Health Companies Inc. has a 52 week low of C$6.10 and a 52 week high of C$12.65. The company has a quick ratio of 0.58, a current ratio of 1.56 and a debt-to-equity ratio of -1,559.86. The firm has a 50 day moving average of C$8.99 and a 200 day moving average of C$7.98.
Bausch Health Companies (TSE:BHC - Get Free Report) last announced its earnings results on Wednesday, October 28th. The company reported C$2.52 earnings per share (EPS) for the quarter. The business had revenue of C$4.19 billion for the quarter. Bausch Health Companies had a positive return on equity of 57.67% and a negative net margin of 7.43%. On average, sell-side analysts predict that Bausch Health Companies Inc. will post 5.55 earnings per share for the current fiscal year.
Bausch Health Companies declared that its board has approved a stock buyback program on Wednesday, October 28th that authorizes the company to repurchase C$70 million in shares. This repurchase authorization authorizes the company to buy up to 1.9% of its stock through open market purchases. Share repurchase programs are often an indication that the company's board believes its stock is undervalued.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group raised Bausch Health Companies to a "hold" rating in a research report on Wednesday, July 22nd. Three analysts have rated the stock with a Hold rating. According to data from MarketBeat, the stock has a consensus rating of "Hold".
Get Our Latest Report on Bausch Health Companies
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
